Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: Case report and review of the literature

Pharmacotherapy

Volumn 27, Issue 1, 2007, Pages 152-160

  McClaskey, Elizabeth M ^a   Michalets, Elizabeth Landrum ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Mission Hospital   (United States)

^c Department of Pharmacy ^*  (United States)

Author keywords

Aspirin; Bleeding risk; Drug interaction; Fish oil; Omega 3 fatty acids; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DOCOSAHEXAENOIC ACID; FISH OIL; FUROSEMIDE; GLIPIZIDE; ICOSAPENTAENOIC ACID; IPRATROPIUM BROMIDE; LEVOTHYROXINE; LORAZEPAM; METFORMIN 4 CHLOROPHENOXYACETATE; MIGLITOL; OMEGA 3 FATTY ACID; PLACEBO; POTASSIUM CHLORIDE; RAMIPRIL; SIMVASTATIN; VITAMIN K GROUP; WARFARIN;

ADD ON THERAPY; AGED; ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; ARTIFICIAL HEART PACEMAKER; ASTHMA; BLEEDING; BLEEDING TIME; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CASE REPORT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CRANIOTOMY; DIET SUPPLEMENTATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; EPISTAXIS; FALLING; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HEART INFARCTION; HEMATURIA; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; MALE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POLYPHARMACY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RISK; RISK BENEFIT ANALYSIS; SICK SINUS SYNDROME; SIDE EFFECT; STROKE; SUBDURAL HEMATOMA; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME;

ACCIDENTAL FALLS; AGED; ANTICOAGULANTS; ASPIRIN; DRUG INTERACTIONS; FATTY ACIDS, OMEGA-3; HEMATOMA, SUBDURAL; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; WARFARIN;

EID: 33846043507     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.1.152     Document Type: Review

References (57)

1. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385-91.
2. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the gruppo Italiano per lo studio della sopravvivenza nell'infarcto miocardico (GISSI)-prevenzione. Circulation 2002;105:1897-903.
3. Smith P, Arnessen H, Opstad T, Dahl KH, Eritsland E. Influence of highly concentrated n-3 fatty acids on serum lipids and hemostatic variables in survivors of myocardial infarction receiving either oral anticoagulants or matching placebo. Thromb Res 1989;53:467-74.
4. Chin JPF. Marine oils and cardiovascular reactivity. Prostaglandins Leukot Essent Fatty Acids 1994;50:211-22.
5. Reliant Pharmaceuticals, Inc. Omacor (omega-3-acid ethyl esters) package insert. Liberty Corner, NJ; 2005.
6. American Heart Association. AHA recommendation on fish and omega-3 fatty acids. Available from http://www.american heart.org/presenter.jhtml? identifier=4632. Accessed November 28, 2005.
7. Vanschoonbeek K, de Maat MPM, Heemskerk JWM. Fish oil consumption and reduction of arterial disease. J Nutr 2003;133:657-60.
8. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996;77:31-6.
9. Leaf A. On the reanalysis of the GISSI-prevenzione. Circulation 2002;105:1874-5.
10. Keli SO, Feskens EJM, Kromhout D. Fish consumption and risk of stroke: the Zutphen study. Stroke 1994;2:328-32.
11. Mortensen JZ, Schmidt EB, Nielsen AH, Dyerberg J. The effect of n-6 and n-3 polyunsaturated fatty acids on hemostasis, blood lipids and blood pressure. Thromb Haemost 1983;50:543-6.
12. Lewis CJ. Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease [letter]. Available from http://vm.cfsan.fda.gov/-dms/ds-ltr11.html. Accessed November 30, 2005.
13. Meydani SN, Dinarello CA. Influence of dietary fatty acids on cytokine production and its clinical implications. Nutr Clin Pract 1993;8:65-72.
14. Gerster H. N-3 fish oil polyunsaturated fatty acids and bleeding. J Nutr Environ Med 1995;5:281-96.
15. Nieuwenhuys CMA, Beguin S, Offermans FG, Emeis JJ, Hornstra G, Heemskerk JWM. Hypocoagulant and lipid-lowering effects of dietary n-3 polyunsaturated fatty acids with unchanged platelet activation in rats. Arterioscler Thromb Vasc Biol 1998;18:1480-9.
16. Malle E, Kostner GM. Effects of fish oils on lipid variables and platelet function indices. Prostaglandins Leukot Essent Fatty Acids 1993;49:645-63.
17. Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr 1997;65(suppl):S1687-98.
18. Bang HO, Dyerberg J. The bleeding tendency in Greenland Eskimos. Dan Med Bull 1980;27:202-5.
19. Lenzi S, Caprioli R, Rindi P, et al. Omega-3 fatty acid supplementation and lipoprotein(a) concentrations in patients with chronic glomerular diseases. Nephron 1996;72:383-90.
20. Goodnight SH, Harris WS, Connor WE. The effects of dietary omega-3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood 1981;58:880-5.
21. DeCaterina R, Giannessi D, Mazzone A, et al. Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. Circulation 1990;82:428-38.
22. Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994;90:2248-57.
23. Bairati I, Roy L, Meyer F. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty. Circulation 1992;85:950-6.
24. Clarke JTR, Cullen-Dean G, Regelink E, Chan L, Rose V. Increased incidence of epistaxis in adolescents with familial hypercholesterolemia treated with fish oil. J Pediatr 1990;116:139-41.
25. Bowles MH, Klonis D, Plavac TG, et al. EPA in the prevention of restenosis post PTCA. Angiology 1991;42:187-94.
26. Eritsland J, Arnesen H, Seljeflot I, Kierulf P. Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagul Fibrinolysis 1995;6:17-22.
27. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. Ann Pharmacother 2004;38:50-2.
28. GISSI-Prevenzione Investigators. Dietary supplement with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. Lancet 1999;354:447-55.
29. Bang HO, Dyerberg J. Plasma lipid and lipoprotein pattern in Greenlandic west-coast Eskimos. Lancet 1971;1;1143-5.
30. Connor WE. N-3 fatty acids from fish and fish oil: panacea or nostrum? Am J Clin Nutr 2001;74:415-16.
31. Pendersen HS, Mulvad G, Seidelin KN, Malcom GT, Boudreau DA. N-3 fatty acids as a risk factor for haemorrhagic stroke. Lancet 1999;353:812-13.
32. Mutanen M, Freese R. Fats, lipids and blood coagulation. Curr Opin Lipidol 2001;12:25-9.
33. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205-9.
34. Daviglus ML, Stamer J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 1997;336:1046-53.
35. Dolecek TA. Epidemiological evidence of relationships between dietary polyunsaturated fatty acids and mortality in the multiple risk factor intervention trial. Proc Soc Exp Biol Med 1992;200:177-82.
36. Rodriguez BL, Sharp DS, Abbott RD, et al. Fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers. The Honolulu heart program. Circulation 1996;94:952-6.
37. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-61.
38. Burr ML, Sweetham PM, Fehily AM. Diet and reinfarction. Eur Heart J 1994;15:1152-3.
39. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454-9.
40. Albert AM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998;279:23-8.
41. Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega-3 fats for mortality, cardiovascular disease, and cancer: a systematic review. BMJ 2006;332:752-60.
42. 12 and reduction of platelet aggregation with n-3 fatty acids. Thromb Res 2000;100:153-60.
43. Lefevre M, Kris-Etherton PM, Zhao G, Tracy RP. Dietary fatty acids, hemostasis, and cardiovascular disease risk. J Am Diet Assoc 2004;104:410-19.
44. Harris WS, Silveira S, Dujovne CA. The combined effects of n-3 fatty acids and aspirin on hemostatic parameters in man. Thromb Res 1990;57:517-26.
45. Thomgren M, Gustafson A. Effects of 11-week increases in dietary eicosapentanoic acid on bleeding time, lipids, and platelet aggregation. Lancet 1981;2:1190-3.
46. Dehmer GJ, Popma JJ, van den Berg EK, et al. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Engl J Med 1988;319:733-40.
47. Shahar E, Folsom AR, Wu KK, et al. Associations of fish intake and dietary n-3 polyunsaturated fatty acids with a hypocoagulable profile: the atherosclerosis risk in communities (ARIC) study. Arterioscler Thromb 1993;13:1205-12.
48. Andreotti F, Testa L, Biondi-Zoccai GGL, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an update and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006;27:519-26.
49. Gurwitz JH, Avorn J, Ross-Degan D, Choodnovsky I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992;116:901-4.
50. Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarn. Ann Intern Med 1996;124:970-9.
51. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
52. Pengo V, Barbero F, Banzato A, et al. A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses. Thromb Haemost 1997;77:839-44.
53. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:S287-310.
54. Torn M, Bollen WLEM, van der Meer FJM, van der Wall EE, Rosendaal FR. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005;165:1527-32.
55. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
56. Wood MJ, Sterwart RL, Merry H, Johnstone DE, Cox, JL. Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am Heart J 2003;145:806-12.
57. Ramsay NA, Kenny MW, Davies G, Patel JP. Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol 2005;130:777-80.